IRLAB Therapeutics AB (publ) (ST:IRLAB-A) — Market Cap & Net Worth
Market Cap & Net Worth: IRLAB Therapeutics AB (publ) (IRLAB-A)
IRLAB Therapeutics AB (publ) (ST:IRLAB-A) has a market capitalization of $15.76 Million (Skr146.47 Million) as of September 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #25934 globally and #530 in its home market, demonstrating a -9.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IRLAB Therapeutics AB (publ)'s stock price Skr1.73 by its total outstanding shares 84858244 (84.86 Million). Also see how large is IRLAB Therapeutics AB (publ)'s balance sheet for a full breakdown of the balance sheet.
IRLAB Therapeutics AB (publ) Market Cap History: 2017 to 2026
IRLAB Therapeutics AB (publ)'s market capitalization history from 2017 to 2026. Data shows change from $256.64 Million to $15.76 Million (-18.07% CAGR). Also see IRLAB Therapeutics AB (publ) cash flow conversion for how efficiently the company converts equity into cash flow.
IRLAB Therapeutics AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IRLAB Therapeutics AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check IRLAB-A live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.31x
IRLAB Therapeutics AB (publ)'s market cap is 0.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $256.64 Million | $109.00K | -$56.23 Million | 2354.53x | N/A |
| 2018 | $565.33 Million | $18.00K | -$74.10 Million | 31407.43x | N/A |
| 2019 | $328.43 Million | $26.00K | -$96.32 Million | 12632.02x | N/A |
| 2020 | $383.55 Million | $300.00K | -$91.85 Million | 1278.49x | N/A |
| 2021 | $401.81 Million | $207.78 Million | $51.78 Million | 1.93x | 7.76x |
| 2022 | $349.76 Million | $61.14 Million | -$114.20 Million | 5.72x | N/A |
| 2023 | $68.49 Million | $5.68 Million | -$177.84 Million | 12.06x | N/A |
| 2024 | $98.17 Million | $94.63 Million | -$83.13 Million | 1.04x | N/A |
| 2025 | $17.99 Million | $57.46 Million | -$110.01 Million | 0.31x | N/A |
Competitor Companies of IRLAB-A by Market Capitalization
Companies near IRLAB Therapeutics AB (publ) in the global market cap rankings as of September 19, 2026. Review IRLAB Therapeutics AB (publ) tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to IRLAB Therapeutics AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
IRLAB Therapeutics AB (publ) Historical Marketcap From 2017 to 2026
Between 2017 and today, IRLAB Therapeutics AB (publ)'s market cap moved from $256.64 Million to $ 15.76 Million, with a yearly change of -18.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr15.76 Million | -12.39% |
| 2025 | Skr17.99 Million | -81.67% |
| 2024 | Skr98.17 Million | +43.33% |
| 2023 | Skr68.49 Million | -80.42% |
| 2022 | Skr349.76 Million | -12.95% |
| 2021 | Skr401.81 Million | +4.76% |
| 2020 | Skr383.55 Million | +16.78% |
| 2019 | Skr328.43 Million | -41.90% |
| 2018 | Skr565.33 Million | +120.28% |
| 2017 | Skr256.64 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of IRLAB Therapeutics AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.76 Million USD |
| MoneyControl | $15.76 Million USD |
| MarketWatch | $15.76 Million USD |
| marketcap.company | $15.76 Million USD |
| Reuters | $15.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pir… Read more